Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1743 • 2016 ACR/ARHP Annual Meeting
Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features
Osvaldo Luis Cerda, Margarita Landi, Cecilia Zaffarana, Josefina Gallino Yanzi, Emilce Schneeberger and Gustavo Citera, Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Cervical inflammatory pain is very common and rarely studied in patients with Psoriatic Arthritis (PsA). The purpose of our study was to evaluate the…
Abstract Number: 1687 • 2016 ACR/ARHP Annual Meeting
Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Laura C. Coates², Catherine L. Shuler³, Chen-Yen Lin³, Susan R. Moriarty³, Chin H. Lee³ and Philip J Mease⁴, ¹Tufts University School of Medicine, Boston, MA, ²University of Leeds, Leeds, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. Ixekizumab (IXE) is an IgG4 mAb that binds…
Abstract Number: 2006 • 2016 ACR/ARHP Annual Meeting
Tuberculosis Incidence in Ankylosing Spondylitis, Psoriatic Arthritis, and Other Spondyloarthropathies in Sweden: A Population-Based Cohort Study
Mirjam K. de Vries¹, Elizabeth V. Arkema¹, Jerker Jonsson², Judith Bruchfeld³, Lennart TH Jacobsson⁴ and Johan Askling^1,5, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Infectious Diseases Unit, Karolinska University Hospital, The Public Health Agency of Sweden, Stockholm, Sweden, ³Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a well-documented increased risk of tuberculosis (TB) compared to the general population, both with and without treatment…
Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Omer Karadag¹, Ediz Dalkilic², Ahmet Mesut Onat³, Orhan Kucuksahin⁴, Timucin Kasifoglu⁵, Bunyamin Kisacik⁶, Omer Nuri Pamuk⁷, Neslihan Yilmaz⁸, Suleyman Serdar Koca⁹, Veli Yazisiz¹⁰, Pinar Talu Ocakci¹¹, Mehmet Sayarlioglu¹², Ender Terzioglu¹³, Sukran Erten^14,15, Mustafa Ferhat Oksuz¹⁶ and Umut Kalyoncu¹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁶Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁷Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁸Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁹Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, ¹⁰Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹¹Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, ¹²Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ¹³Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁴Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, ¹⁵Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁶Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…
Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Laura C. Coates¹, M. Elaine Husni², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Chin H. Lee³ and Philip J Mease⁴, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 2169 • 2016 ACR/ARHP Annual Meeting
Presence of Cardiovascular Risk Factors Across Different Inflammatory Joint Disease Entities: Results from a Norwegian, Multi-Centre Project
Grunde Wibetoe¹, Eirik Ikdahl², Silvia Rollefstad², Anne Salberg³, Dag Magnar Soldal⁴, Tore K Kvien⁵, Glenn Haugeberg⁶ and Anne Grete Semb⁷, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Martina Hansens Hospital, Bærum, Norway, ⁷Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: EULAR recommendations for cardiovascular disease (CVD) risk management in inflammatory joint diseases (IJD) advocates annual CVD risk assessments to reduce the increased CVD risk.…
Abstract Number: 148 • 2016 ACR/ARHP Annual Meeting
Which Are the Ultrasound Lesions Underlying Dactylitis?
Adrien Nzeusseu Toukap¹, Anne Durnez², Pablo Navarro Guerra³ and Maria Stoenoiu⁴, ¹Department of Rheumatology, Cliniques Universitaires St Luc, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, AZ Jan Portaels, Brussels, Belgium, ³Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Service de Rhumatologie, Cliniques Universitaires Saint-Luc,Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain,, Brussels, Belgium
Background/Purpose: Dactylitis (DACT) is defined as diffuse swelling of the digit and is included in the ASAS criteria for spondyloarthritis. It is a hallmark feature of…
Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, M. Elaine Husni², Catherine L. Shuler³, Russel T. Burge³, Chen-Yen Lin³, Chin H. Lee³ and D Gladman⁴, ¹Tufts University School of Medicine, Boston, MA, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 158 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Is a Sensitive Imaging Tool for the Assessment of Dynamic Changes of Bone Erosions in Inflammatory Arthritis: A Comparative Analysis with High-Resolution Peripheral Quantitatve Computed Tomography
Stephanie Finzel^1,2, Marina Backhaus³, Sebastian Kraus⁴, Georg Schett⁵ and Reinhard Voll⁶, ¹Department of Rheumatology and Clinical Immunology, Medical Faculty, University Medical Center, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine III, Rheumatology and Immunology, University of Erlangen, 91054, Germany, ³Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany
Background/Purpose: Correct detection of bone erosions is crucial both for diagnosis and for monitoring of treatment response in patients with inflammatory joint diseases. Musculoskeletal ultrasound…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…
Abstract Number: 2747 • 2016 ACR/ARHP Annual Meeting
Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis
Umut Kalyoncu, Ozun Bayndır, Mustafa Ferhat Oksuz, Gezmis Kimyon, Abdulsamet Erden, Sule Yavuz, Gozde Cetin, Orhan Kucuksahin, Levent Kilic, Ahmet Omma, Cem Ozisler, Dilek Solmaz, Ahmet Mesut Onat, Bunyamin Kisacik, Duygu Ersozlu Bakirli, Muhammet Cinar, Abdurrahman Tufan, Fatih Yildiz, Ridvan Mercan, Timucin Kasifoglu, Baris Yilmazer, Sema Yilmaz, Kenan Aksu, Sukran Erten, Mehmet Sayarlioglu, Ediz Dalkilic, Servet Akar, Cengizhan Acikel, Muge Aydin Tufan, Ayse Balkarli, Esen Kasapoglu-Gunal, Soner Senel, Senol Kobak, M Tuncay Duruoz, Atalay Dogru, E.Figen Tarhan, Meryem Can, Lutfi Akyol, Seval Pehlevan, Funda Erbasan, Fatos Arslan, Adem Kucuk, Emel Gonullu, Yasemin Kabasakal, Mehmet Sahin, Nilgun Atakan and Sibel Z. Aydin, PsART study group, Ankara, Turkey
Background/Purpose: Disease Activity index for Psoriatic Arthritis (DAPSA) originally developed from patients with reactive arthritis and validated in psoriatic arthritis (PsA) patients. DAPSA includes…
Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Stefano Alivernini¹, Luca Petricca¹, Laura Bui², Barbara Tolusso¹, Gabriele Di Sante¹, Roberta Benvenuto², Anna Laura Fedele¹, Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…
Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Peter Nash¹, Kamal Ohson², Jessica Walsh³, Nikolay Delev⁴, Dianne Nguyen⁴, Lichen Teng⁴, Juan J Gomez-Reino⁵ and Jacob A Aelion⁶, ¹University of Queensland, Brisbane, Australia, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Celgene Corporation, Summit, NJ, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…
Abstract Number: 2930 • 2016 ACR/ARHP Annual Meeting
Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Rui Carvalho¹, Christine Tucher², Lars Tykocinski², Susanne Neu², Karel Klika³, H.-M. Lorenz² and Margarida Souto-Carneiro², ¹Life Sciences Department, FCTUC, Center for Functional Ecology, University of Coimbra, Coimbra, Portugal, ²Rheumatology, Department of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³German Cancer Research Center, Heidelberg, Germany
Background/Purpose: Studies by our team and others have shown that CD8 T cells (CD8s) in RA have a pro-inflammatory, cytotoxic effector phenotype and may, therefore,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].